Clinical Monograph for Drug Formulary Review: Systemic Agents for Psoriasis/Psoriatic Arthritis

BACKGROUND: Significant advances in the pharmacologic treatment of psoriasis,most notably the introduction of the biologic agents efalizumab and alefacept,have occurred recently. In addition, another biologic agent, etanercept, was recently approved for the treatment of psoriasis and psoriatic arthr...

Descripción completa

Detalles Bibliográficos
Autor principal: Fisher, Vicki S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2005
Materias:
Formulary Management
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437546/
https://www.ncbi.nlm.nih.gov/pubmed/15667232
http://dx.doi.org/10.18553/jmcp.2005.11.1.33

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437546/
https://www.ncbi.nlm.nih.gov/pubmed/15667232
http://dx.doi.org/10.18553/jmcp.2005.11.1.33

Ejemplares similares